AmplifyBio spun out from Battelle in 2021 as a preclinical CRO with decades of experience designing and delivering in vivo safety, efficacy, and toxicology studies for the preparation of IND packages. Since its launch, AmplifyBio has steadily expanded services to support the discovery, characterization, optimization, and manufacturing of a broader range of drug modalities and become the industry’s preferred advanced therapy development and commercialization partner. Working with AmplifyBio reduc...uces timelines and mitigates risks at every stage by integrating the right expertise, assay technologies, and data solutions.